ArticleSubstance abuse treatment, prevention, and policy2026
The relationship between methadone dosage and plasma level changes with aging in methadone maintenance treatment (MMT) patients.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs aging is associated with physiological changes, patients in methadone maintenance treatment (MMT) may require an adequate methadone dose adjustment. We aimed to study the relationship between aging and methadone dose and plasma level.
methodsPatients with two methadone plasma level results, above one year apart, were included. Methadone dose and plasma levels, as well as their changes over time, were studied by age group.
results318 patients, 36.5% aged <50 years, 53.5% 50–64, and 10.1% aged ≥65 years, were compared. Methadone dose did not differ between groups (120.8±38.6 mg/day); however, methadone plasma levels were lowest in the <50y group (580.9±270.9 ng/ml), followed by the 50–64y group (715.4±345.1 ng/ml), and highest in the ≥65y group (893.1±379 ng/ml, p<0.001). This was also reflected in the proportion of patients with (≥1000 ng/ml methadone plasma levels): 6.9%, 18.8%, and 37.5%, respectively (p<0.001). Groups also differed in BMI, which was lowest in the ≥65 years group (24.8±3.9), compared to 26.0±5.5 in the <50 and 26.9±5.1 in the 50–64.9 age group (p=0.053). Methadone plasma levels still significantly differed by age group (p<0.001) after controlling for methadone dose (p<0.001) and BMI (p=0.02) (ANOVA, corrected model p<0.001, F=37.8). Following 4.6±1 years, at the latest evaluation, both methadone doses (Repeated Measures p(Time)=0.004) and plasma levels (p(Time)=0.002) were reduced, with no interaction by age group (p(Time*Group)=0.4 and 0.5, respectively), but only methadone plasma levels differed by age groups (p(Group)<0.001). The proportion of ≥1000 ng/ml methadone plasma levels remained significantly higher among the older age group.
conclusionsAlthough the dose of methadone does not require elevation over the years, due to aging, methadone plasma level evaluation should be considered to avoid excessively high methadone plasma levels. However, as the older group represented a small subgroup, additional larger cohort studies and future follow-up are needed to confirm our preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.